Results 31 to 40 of about 4,565 (192)

Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report

Frontiers in Pharmacology, 2021
Tumour lysis syndrome (TLS) represents a group of fatal metabolic derangements resulting from the rapid breakdown of tumour cells. TLS typically occurs soon after the administration of chemotherapy in haematologic malignancies but is rarely observed in ...
Yadong Wang, Yadong Wang, Tiange Wang, Tiange Wang, Jianchao Xue, Jianchao Xue, Ziqi Jia, Ziqi Jia, Xinyu Liu, Xinyu Liu, Bowen Li, Bowen Li, Ji Li, Xiaoguang Li, Weiwei Wang, Zhongxing Bing, Lei Cao, Zhili Cao, Naixin Liang   +18 more
doaj   +1 more source

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis

Frontiers in Oncology, 2022
BackgroundBrigatinib is a central nervous system-active second-generation anaplastic lymphoma kinase (ALK) inhibitor that targets a broad range of ALK rearrangements in patients with non-small cell lung cancer (NSCLC).
Puyuan Xing, Xuezhi Hao, Xin Zhang, Junling Li   +3 more
doaj   +1 more source

MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. [PDF]

, 2019
Lung cancer remains the most lethal cancer among men and women in the United States and worldwide. The majority of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Developing new therapeutics on the basis of better understanding of
Petrek, Hannah, Yu, Ai-Ming
core   +1 more source

Isolated progression of miliary brain metastasis in a patient with stable lung adenocarcinoma successfully treated with whole-brain radiotherapy: A case report

eNeurologicalSci, 2021
Miliary brain metastasis is a rare form of metastasis commonly associated with advanced stages of cancer. In this article, we report a case of a 38-year-old male with solitary progression of miliary brain metastasis originating from stage 4 EML-ALK ...
Satomi Hiya, Satoru Fujiwara, Atsushi Nakagawa, Yuki Sato, Yoshihiro Omura, Shigeo Hara, Nobuo Kohara, Michi Kawamoto   +7 more
doaj   +1 more source

Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients [PDF]

, 2017
Background: The identification of anaplastic lymphoma kinase (ALK) rearrangements is found in approximately 5% of non-small-cell lung cancers (NSCLCs).
Calvo, Virginia, Coronado, María José, Cruz-Bermúdez, Alberto, Cruz-Bermúdez, Juan Luis, Franco, Fernando, García-Grande, Aránzazu, Gutiérrez, Lourdes, Martín Ruiz-Valdepeñas, Asunción, Martín, Paloma, Provencio, Mariano, Pérez-Callejo, David, Romero, Atocha, Sánchez-Beato, Margarita, Torrente, María   +13 more
core   +3 more sources

YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs

JTO Clinical and Research Reports, 2022
Introduction: ALK tyrosine kinase inhibitors (TKIs) are the standard treatment for advanced ALK-positive NSCLC. Nevertheless, drug resistance inevitably occurs.
Roberta Minari, PhD, Samuel Valentini, MSc, Denise Madeddu, PhD, Andrea Cavazzoni, PhD, Silvia La Monica, PhD, Costanza Anna Maria Lagrasta, MSc, Roberto Bertorelli, MSc, Veronica De Sanctis, PhD, Paola Fassan, MSc, Cinzia Azzoni, PhD, Lorena Bottarelli, PhD, Caterina Frati, PhD, Letizia Gnetti, MD, Francesco Facchinetti, MD, Pier Giorgio Petronini, PhD, Roberta Alfieri, PhD, Alessandro Romanel, PhD, Marcello Tiseo, MD, PhD   +17 more
doaj   +1 more source

Modern treatment of ALK-positive non-small cell lung cancer

Южно-Российский онкологический журнал, 2022
Lung cancer (LC) takes the first place in the structure of overall oncology in males. More than 1.8 million of new cases of lung cancer (LC) are registered each year worldwide.
D. A. Kharagezov, Yu. N. Lazutin, E. A. Mirzoyan, A. G. Milakin, O. N. Stateshny, I. A. Leyman, M. A. Gappoeva, V. N. Vitkovskaya, K. D. Iozefi   +8 more
doaj   +1 more source

Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. [PDF]

, 2017
Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified in lung cancer at 3-7% frequency, thus representing an important subset of genetic lesions that drive oncogenesis in this disease. Despite the availability of multiple FDA-approved
Bivona, Trever G, Haderk, Franziska, Wu, Wei   +2 more
core   +3 more sources

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System [PDF]

, 2022
open7siBackground The development of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) has improved the survival outcomes of patients with advanced ALK-rearranged non-small-cell lung cancer (NSCLC).
Ardizzoni, Andrea, De Giglio, Andrea, Facchinetti, Francesco, Fusaroli, Michele, Gelsomino, Francesco, Raschi, Emanuel, Sisi, Monia   +6 more
core   +1 more source

Emerging EGFR-Mutated Subclones in a Patient With Metastatic ALK-Rearranged Lung Adenocarcinoma Treated With ALK-Targeted Therapy: A Case Report

JTO Clinical and Research Reports, 2023
We report a case of pathologically confirmed ALK-rearranged metastatic lung adenocarcinoma with emergence of EGFR L858R mutation on disease progression after two lines of treatment with ALK inhibitors.
Jackson Ka Chun Leung, M.B.B.S., Wang Chun Kwok, M.B.B.S., Arthur Chun Fung Leung, M.B.B.S., Po Tsui, FHKCPath, James Chung-Man Ho, MD, FRCP   +4 more
doaj   +1 more source